ARTICLE | Company News
Altea, Amylin, Eli Lilly deal
April 6, 2009 7:00 AM UTC
Altea granted Lilly and Amylin exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's PassPort Transdermal Delivery System. The once daily transdermal exenatide patch is in Phase I testing for Type II diabetes. Altea will receive an undisclosed upfront payment and is eligible for up to $46 million in milestones, plus royalties. Lilly and Amylin also will each make an undisclosed equity investment in Altea. ...